Article

Improvement of afterload mismatch of left atrial booster pump function with positive inotropic agent.

Second Department of Internal Medicine, Yamaguchi University School of Medicine, Japan.
Journal of the American College of Cardiology (Impact Factor: 14.09). 01/2001; 37(1):270-7. DOI: 10.1016/S0735-1097(00)01060-3
Source: PubMed

ABSTRACT The objective of this study was to examine the hypothesis that a positive inotropic agent improves left ventricular (LV) filling during left atrial (LA) contraction in the presence of markedly elevated LV filling pressure.
In patients with old myocardial infarction (MI), an increase in the operational LV chamber stiffness reduces LV filling during the LA contraction, resulting from an "afterload mismatch" of the LA booster pump function.
We investigated the effect of dobutamine infusion (3 microg/kg/min) on the LA pump function in the presence of elevated LV filling pressure induced by aortic constriction (Aoc) during acute MI in 10 dogs. Transmitral flow velocity was determined by transesophageal echocardiography, LV pressure by a micromanometer and LV volume by a conductance catheter. We measured the early (E) and late (A) diastolic peak transmitral flow velocities (cm/s) and LV chamber stiffness (deltaP/deltaV: mm Hg/ml; where deltaP is developed pressure and deltaV is the absolute filling volume during LA contraction).
When the deltaP/deltaV was increased by Aoc during MI (from 1.1 +/- 0.8 to 3.1 +/- 2.6 mm Hg/ml, p < 0.01), A decreased significantly (from 30 +/- 5 to 22 +/- 8 cm/s, p < 0.01), and the ratio of E to A increased (from 1.0 +/- 0.3 to 1.4 +/- 0.8, p < 0.05) compared with MI without Aoc, showing the pseudonormal transmitral flow pattern, the so called "LA afterload mismatch." Dobutamine under this condition significantly reduced the deltaP/deltaV (to 1.7 +/- 1.2 mm Hg/ml, p < 0.05), resulting in an increase in A (to 31 +/- 8 cm/s, p < 0.01) and a decrease in E/A (to 1.0 +/- 0.3, p < 0.05), and the transmitral flow became a prolonged relaxation pattern as in MI without Aoc in all dogs. There was an inverse correlation between the deltaP/deltaV and the time-velocity integral of A (r = -0.70, p < 0.01).
Dobutamine improved the afterload mismatch of the LA booster pump function. This effect may have been due to the reduction in LV operational chamber stiffness, resulting in an increase in the LA forward ejection into the LV.

0 Bookmarks
 · 
54 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent studies in adults have indicated that left atrial (LA) systolic force (LASF) provides useful information about LA pump function and can be used to predict cardiovascular events. However, normal values of LASF in children are not available, and little is known about atrial function in pediatric patients with heart disease. The objectives of the present study were to provide reference values for LASF in children and to determine LA pump performance in pediatric patients with heart disease using LASF. LASF was measured using combined two-dimensional imaging and Doppler echocardiography in 185 healthy children and 71 pediatric patients with ventricular septal defects (VSDs; as a representative heart disease with chronic left ventricular [LV] volume overload; n=48) or coarctation of the aorta (COA; as a representative heart disease with chronic LV pressure overload; n=23). LASF in children significantly increased with advancing age (P<.005). The major determinants of this change were body surface area, stroke volume, and heart rate, with a linear model fit (r2) of 0.72. In patients with VSD and those with COA, LASF was significantly elevated in proportion to the degree of LV volume or pressure load, suggesting adaptive mechanisms of LA pump function to facilitate LV filling in chronically overloaded hearts. LASF was normalized after anatomic correction of VSDs but remained elevated even after the relief of COA, indicating persistent overwork of the left atrium. The present study provides reference data for the evaluation of atrial function in pediatric patients with cardiac disease. In addition, altered LASF in patients with VSDs with even small left-to-right shunts and in those with COA even after anatomic correction may have pathologic implications that could lead to a novel therapeutic target.
    Journal of the American Society of Echocardiography: official publication of the American Society of Echocardiography 06/2009; 22(8):939-46. · 2.98 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The interest in the left atrium (LA) has resurged over the recent years. In the early 1980s, multiple studies were conducted to determine the normal values of LA size. Over the past decade, LA size as an imaging biomarker has been consistently shown to be a powerful predictor of outcomes, including major public health problems such as atrial fibrillation, heart failure, stroke, and death. More recently, functional assessment of the LA has been shown to be, at least as, if not more robust, a marker of cardiovascular outcomes. Current available data suggest that the combined evaluation of LA size and LA function will augment prognostication. The aim of this review is to provide a critical appraisal of current echocardiographic techniques for the assessment of LA function and the implications of such assessment for prediction and disease prevention.
    European Heart Journal – Cardiovascular Imaging 06/2011; 12(6):421-30. · 2.39 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Assessment of global left ventricular (LV) remodeling is important in evaluating the efficacy of pharmacologic and device therapies for the treatment of chronic heart failure (HF). The effects of pharmacologic or device therapies on global left atrial (LA) remodeling in HF, although also important, are not often examined. We showed that long-term therapy with the Acorn Cardiac Support Device (CSD), a passive mechanical ventricular containment device, prevents or reverses LV remodeling in dogs with HF. This study examined the effects of the CSD on global LA remodeling in dogs with moderate and advanced HF. Studies were performed in 24 dogs with coronary microembolization-induced HF. Of these, 12 had moderate HF (ejection fraction, EF 30% to 40%) and 12 advanced HF (EF < or = 25%). In each group, the CSD was implanted in 6 dogs and the other 6 served as controls. Dogs were followed for 3 months in the moderate group and 6 months in the advanced HF group. LA maximal volume (LAVmax), LA volume at the onset of the p-wave (LAVp), LA minimal volume (LAVmin), LA active emptying volume (LAAEV), and LA active emptying fraction (LAAEF) were measured from 2-dimensional echocardiograms obtained before CSD implantation and at the end of the treatment period. Treatment effect (delta) comparisons between CSD-treated dogs and controls showed that CSD therapy significantly decreased LA volumes (deltaLAVmax: 3.33 +/- 0.70 vs. -2.87 +/- 1.31 mL, P = .002; 7.77 +/- 1.76 versus -0.37 +/- 0.87 mL, P = .002) and improved LA function (deltaLAAEF: -6.00 +/- 1.53 versus 1.85 +/- 1.32%, P = .003; -2.39 +/- 1.10 versus 3.13 +/- 1.66%, P = .02) in the moderate HF and advanced HF groups, respectively. Progressive LA enlargement and LA functional deterioration occurs in untreated dogs with HF. Monotherapy with the CSD prevents LA enlargement and improves LA mechanical function in dogs with moderate and advanced HF indicating prevention or reversal of adverse LA remodeling.
    Journal of cardiac failure 06/2007; 13(4):312-7. · 3.25 Impact Factor

Full-text (2 Sources)

View
13 Downloads
Available from
May 31, 2014